Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib

Japanese Journal of Clinical Oncology

Volumn 43, Issue 10, 2013, Pages 1023-1029

  Nakano, Kazuhiko ^a   Komatsu, Kenji ^a   Kubo, Taro ^a   Natsui, Shinsuke ^a   Nukui, Akinori ^a   Kurokawa, Shinsuke ^a   Kobayashi, Minoru ^a   Morita, Tatsuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Hand Foot skin reaction; Renal cell carcinoma; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; SORAFENIB;

AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER CLASSIFICATION; CLINICAL ARTICLE; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPANESE; KIDNEY CARCINOMA; MALE; METASTASIS; NEPHRECTOMY; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

HAND-FOOT SKIN REACTION; RENAL CELL CARCINOMA; SORAFENIB; TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HAND-FOOT SYNDROME; HEMOGLOBINS; HUMANS; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEPHRECTOMY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84885109918     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt110     Document Type: Article

References (26)

1. Di Fiore F, Rigal O, Menager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer 2011;105: 1811-3.
2. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
4. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand-foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-61.
5. Chu D, Lacouture ME, Fillos T, Wu S. Risk of Hand-Foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008;47:176-86.
6. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51.
7. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011;36:344-50.
8. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?. Eur J Cancer 2006;42:548-56.
9. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92.
10. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543-50.
11. Tanigawa G, Kawashima A, Yamaguchi S, et al. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol 2011;41: 1265-70.
12. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of Hand-Foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11.
13. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME. Development and validation of a prediction index for Hand-Foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012;23: 2103-8.
14. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
15. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005;23: 5235-46.
16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
17. Park SR, Kook MC, Choi IJ, et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010;65:579-87.
18. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-30.
19. Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012;48:1519-24.
20. Zurita AJ, Jonasch E, Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:46-52.
21. Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol Oncol 2011;13:42-50.
22. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
23. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and Hand-Foot skin. Pharmacotherapy 2010;30:52-6.
24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
25. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
26. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013;84:6-13.